MindBio Therapeutics Corp.
MBIO
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.36% | 163.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -53.42% | 186.99% | |||
| Operating Income | 53.42% | -186.99% | |||
| Income Before Tax | -136.68% | -725.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -136.68% | -725.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -71.43% | 800.00% | |||
| Net Income | -139.00% | -705.21% | |||
| EBIT | 53.42% | -186.99% | |||
| EBITDA | 40.68% | -- | |||
| EPS Basic | -144.44% | -800.00% | |||
| Normalized Basic EPS | 54.55% | -1,000.00% | |||
| EPS Diluted | -144.44% | -800.00% | |||
| Normalized Diluted EPS | 54.55% | -1,000.00% | |||
| Average Basic Shares Outstanding | -0.46% | 0.88% | |||
| Average Diluted Shares Outstanding | -0.46% | 0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||